MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates

被引：40

作者：

Turner, Philip J. ^{[1
]}

机构：

[1] AstraZeneca, Infect Discovery Dept, Macclesfield SK10 4TF, Cheshire, England

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2009年 / 63卷 / 02期

关键词：

MYSTIC; Meropenem; Nosocomial isolates; TEST INFORMATION COLLECTION; MEDICAL-CENTERS; SURVEILLANCE;

D O I：

10.1016/j.diagmicrobio.2008.11.004

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program is a longitudinal antimicrobial surveillance Study that has been in existence since 1997 in centers that are actively prescribing meropenem. This report examines the results from the study ill Europe in 2007. A total of 5208 isolates were examined for activity (MIC) of meropenem and other broad-spectrum antibacterial comparators. Cumulative susceptibility rates using Clinical and Laboratory Standards Institute criteria against all methicillin-susceptible staphylococci were imipenem (97.7%) > meropenem (97.3%) > piperacillin/tazobactain (96.2%) > tobramycin (94.2%) > gentamicin (92.0%) > ciprofloxacin (84.0%) > ceftazidime (39.8%). Against all species of Enterobacteriaceae, the rates were meropenem (99.4%) > imipenem (98.3%) > tobramycin (92.0%) > gentamicin (89.5%) > ceftazidime (86.2%) > piperacillin/tazobactam (85.5%) > ciprofloxacin (84.2%). Meropenem was most effective against the nonfermenters, although multidrug-resistant Acinetobacter spp. and imipenem-resistant Pseudomonas aeruginosa strains were reported. The continued need for Surveillance studies Such as MYSTIC is exemplified, and results from these types of surveillance can, hopefully, help in the correct choice of empiric therapy. (c) 2009 Elsevier Inc. All rights reserved.

引用

页码：217 / 222

页数：6

共 13 条

[1]

Clinical and Laboratory Standards Institute, 2018, METH DIL ANT SUSC TE

[2]

Clinical and Laboratory Standards Institute (CLSI), 2007, M100S17 CLSI

[3] Living with ESBLs - Introduction [J].

Cornaglia, G. ;

Garau, J. ;

Livermore, D. M. .

CLINICAL MICROBIOLOGY AND INFECTION, 2008, 14 :1-2

[4]

EDWARDS JR, 1995, SCAND J INFECT DIS, P5

[5] Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility [J].

Jones, RN .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 :1-8

[6] Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program [J].

Korten, Volkan ;

Ulusoy, Sercan ;

Zarakolu, Pinar ;

Mete, Birgul .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2007, 59 (04) :453-457

[7] Surveillance studies: how can they help the management of infection? [J].

Masterton, RG .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 :53-58

[8] Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006) [J].

Rhomberg, Paul R. ;

Deshpande, Lalitagauri M. ;

Kirby, Jeffrey T. ;

Jones, Ronald N. .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2007, 59 (04) :425-432

[9] Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results [J].

Turner, Philip J. .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2008, 60 (02) :185-192

[10] Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program [J].

Turner, Philip J. .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2006, 56 (03) :341-344

← 1 2 →